Background {#Sec1}
==========

Charcot-Marie-Tooth disease (CMT) represents a genetically and phenotypically highly heterogeneous group of disorders of the peripheral nervous system, affecting 9.7--82.3/100,000 individuals in the European population \[[@CR1]\]. All forms of inheritance are observed in CMT and mutations in over 80 genes with diverse functions have been described as disease-causing \[[@CR2]\].

Based on histology and electrophysiology three main types of CMT are recognized: demyelinating (CMT1), axonal (CMT2) and intermediate (I-CMT). CMT1 is characterized by loss of myelin and nerve conduction velocities (NCVs) below 38 m/s in the median motor nerve. CMT2 primarily affects the axons with patients showing normal or slightly reduced NCVs (\> 38 m/s) \[[@CR3], [@CR4]\]. Finally, individuals showing signs of both demyelination and axonal degeneration, with NCVs between 25 and 45 m/s, are classified under I-CMT \[[@CR5]\].

CMT1 accounts for 40--50% of all CMT patients \[[@CR2]\]. The disease affects the myelin sheath, a complex structure made out of layers of highly compacted Schwann cell membrane. It is very sensitive to changes in its protein or lipid composition and alterations lead to inefficient compaction and insulation of the axons resulting in a significant reduction in NCVs \[[@CR6]\]. Over 50% of the total peripheral myelin is made up of four proteins: myelin basic protein (MBP), myelin protein zero (MPZ), peripheral myelin protein 2 (PMP2) and peripheral myelin protein 22 (PMP22) \[[@CR7]\]. A genomic duplication that includes *PMP22* was the first identified genetic cause of CMT (CMT1A) \[[@CR8], [@CR9]\]. Overall, mutations affecting PMP22 and MPZ account for 76% of all CMT1 patients \[[@CR10]\]. While *MBP* has not been implicated in CMT so far, *PMP2* has recently emerged as a novel rare cause of dominant CMT1 \[[@CR11]--[@CR14]\].

PMP2 is a small 14 kDa protein belonging to the fatty acid binding protein family (FABP) \[[@CR15]\]. It is involved in remyelination, stiffening of the myelin sheath and has a suggested role in membrane stacking and lipid transfer \[[@CR15]--[@CR18]\]. Recently, three heterozygous missense mutations in *PMP2* were identified in five families with dominant CMT1 of European (p.Ile43Asn, c.128 T \> A; p.Thr51Pro, c.151A \> C; p.Ile52Thr, c.155 T \> C) and Asian (p.Ile43Asn, c.128 T \> A) descent \[[@CR11]--[@CR14]\]. Notably, all mutations identified so far cluster in adjacent positions on two neighbouring beta-strands of the PMP2 crystal structure and were observed to affect the functional dynamics of the protein (Fig. [1](#Fig1){ref-type="fig"}e) \[[@CR13], [@CR16]\].

Here, we describe the identification of two novel disease-causing mutations in *PMP2* in a Bulgarian and a German family. Fig. 1**a** Pedigrees and segregation analysis of the Bulgarian (Family A) and German (Family B) families. The mutated residue is indicated in red in the available genotyped individuals. Black diamonds indicate clinically affected individuals. Black arrows indicate probands. **b** Electropherograms of c.341 T \> C (Family A) and c.344 T \> C (Family B) changes in the two families carrying novel *PMP2* mutations. **c** The evolutionary conservation of the amino acids affected by the newly identified mutations (red arrows) in PMP2. **d** The location of the two affected residues (red arrows) in relation to the fatty acid coordinating residues (black arrows). **e** Position of the two mutational clusters on the crystal structure of PMP2. The novel mutations are indicated in red (p.Met114Thr) and blue (p.Val115Ala) on the protein structure. "ΔΔG" values are provided for each known CMT-causing mutation (FoldX). **f** Fatty acid coordinating residues (p.Arg107, p.Arg127, p.Tyr129) surrounding the two mutated amino acids on the crystal structure of PMP2. Palmitate is indicated in green

Results {#Sec2}
=======

Clinical representation {#Sec3}
-----------------------

### Family A {#Sec4}

The proband is a 37-year old Bulgarian female (A.III-1) reporting a family history of CMT consistent with autosomal dominant inheritance, with both an affected parent and grandparent (Figs. [1](#Fig1){ref-type="fig"}a, [2](#Fig2){ref-type="fig"}a). The disease onset of patient A.III-1 was in childhood, with delayed walking at the age of 18 months with frequent falls (Table [1](#Tab1){ref-type="table"}). She had always run slower compared to her peers. She has had difficulties in stepping on her heels and toes since the age of 2--3 years. Foot deformities (high arched feet, thin calves) became apparent in the first decade of life. During her teens proximal muscle weakness in the lower limbs was noticed with difficulties in climbing stairs. The patient was referred to the department of neurology at the age of 20 and was followed up for 17 years. From the age of 29 years she started having weakness in the distal hand muscles with impairment of the fine movements, as well as tingling in the fingers bilaterally. Neurophysiological examinations from four consecutive tests, performed in 2001, 2011, 2016 and 2018 are presented in Table [2](#Tab2){ref-type="table"}. Nerve conduction studies (NCS) were consistent with severe demyelination and secondary axonal degeneration. There are absent sensory responses in both upper and lower limbs. At the age of 37 years the compound muscle action potentials (CMAPs) in the lower limbs were unobtainable. In the upper limbs, CMAPs had severely reduced CV, prolonged distal latencies and low amplitudes. Needle EMG showed scattered fibrillation potentials and neurogenic motor unit action potentials. Fig. 2**a** Clinical features of individual A.III-1, aged 37 years, demonstrating bilateral *pes cavus*, distal hypotrophies in both calves and muscle hypotrophies in the hands, more pronounced for the thenar muscle in comparison with the hypothenar ones. **b**-**e**. Magnetic resonance images of individual A.III-1 performed at the age of 37 years. Non-enhanced T1, T2 and proton density (PD) images are shown. **b**-**d**. The lateral compartments of the calves, including peroneus longus and brevis muscles are more severely affected, followed by *extensor digitorum brevis* and *tibialis anterior* muscles. The posterior compartment of the calves seems relatively preserved. **e** At thigh level the muscles are preserved as well, with slight changes visible in semimembranosus and semitendinosus muscles Table 1Clinical comparison of all reported patients carrying *PMP2* mutationsPatientA.III-1A.II-2B.II-2B.II-1Hong YB et al.Motley W et al. 2016Gonzaga-Jauregui et al. 2015Punetha J et al. 2018II-4III-1III-3Family I/II.3Family I/III.2Family II/II.3.1Family II/IV.5Family II/IV.1Mutation in *PMP2*p.M114 Tp.M114 Tp.V115Ap.V115Ap.I43Np.I43Np.I43Np.I52Tp.I52Tp.T51Pp.T51Pp.T51Pp.I43Np.I52TSexFMMMFMMMMFFFMFAge at onset1.5 y1 y2--3 y2--3 y18 y6 y8 y17 y3 y5 yNR18 mo65First symptomsDelay in starting to walk, frequent fallsWalking with frequent fallsSlight clumsiness during physical activitiesSlight clumsiness foot deformityDistal leg muscle weaknessFrequent fallingDistal leg muscle weaknessFoot drop, frequent fallingImpaired coordination, frequent fallingDistal leg muscle weaknessDistal leg muscle weaknessDelay in starting to walkNRDistal leg muscle weaknessAge of involvement of upper limbs29 y34 y40 y40 y41 y20 y28 yNRNo involvementNRNRNo involvementNRNRAge at last examination37 y34 y44 y45 y58 y38 y36 y48 y13 y37 y13 y24 yNR21WEAKNESS: LOWER LIMBS (MRC SCALE) Knee flexion/extension4/54/55/55/5NRNENE5/55/5NRNR5/5NRNR Foot dorsiflexion1/52/54/55/54/5\< 4/54/54−/53/50/5NR1/5NRNR Plantar flexion3/53/54/55/5NRNRNR5/55/50/5NR4/5NRNR Great toe extension0/51/54/55/5NRNRNR0/53/50/5NR0/5NRNRWEAKNESS: UPPER LIMBS (MRC SCALE) Elbow flexion/extension5/55/55/55/5NRNRNR5/55/5NRNR5/5NRNR Wrist flexion4/55/55/55/5NRNRNR5/55/5NRNR5/5NRNR Wrist extension4/55/55/55/5NRNRNR5/55/5NRNR5/5NRNR Finger flexion3+/5455/55/54/5NR\< 4/55/55/5NR4/53--4/5NRNR Finger extension4/54/55/55/54/5NR\< 4/55/55/5NR4/53--4/5NRNR Thumb abduction3/54/55/55/5NRNRNR4−/55/5More affected than the other intrinsic hand muscles4/51/5NRNRREFLEXES Brachioradial--+/−--+/−NRNRNRNR+/−+/−+------ Biceps+/−+/−----NRNRNR--+/−+/−+------ Triceps+/−+/−----NRNRNRNR+/−+/−+------ Patellar------------+/−-------------- Achille------------+/−--------------SENSATION MODALITIES: LOWER LIMBS SuperficialDDNNDDDDDDNDDNR VibrationDDNNDDDDDNRNDDNR Romberg sign++NENENRNRNRNRNRNRN+NRNRSENSATION MODALITIES: UPPER LIMBS SuperficialNNNNDDDNNNRNDDNR VibrationNNNNDDDNNNRNDDNR Independent ambulationPreserved/steppagePreserved/steppagePreservedPreservedPreservedPreservedPreservedPreservedPreservedPreserved with difficultiesPreservedPreservedNRPreserved/steppage Walking aids usedNoNoOrthopedic shoesNoAnkle-foot orthosesAnkle-foot orthosesAnkle-foot orthosesAnkle foot orthosesNRNRNRNRNRNo Skeletal deformitiesPes cavus and equinovarusPes cavus and equinovarusPes varus L \> RPes varusPes cavusPes cavusPes cavusNRPes cavusPes cavus and equinovarusPes equinovarusPes equinovarusPes cavus,Pes cavus at the age of 12 yPes planus at the age of 20 y Foot deformity surgeryNoYes, at the age of 26 yOn the left foot at the age of 41 yNoNRNoAchilles tendon lengtheningSurgery at the age of 11NRAt the age of 11 yNRTwo on the right foot Muscle atrophySevere for calf, peroneal, foot muscles and milder for thenar and hypothenar musclesModerate for calf, peroneal, foot musclesMild for calf, peroneal, foot musclesNoMild (U \< L)Moderate (U \< L)Mild (U \< L)NRAtrophy of calf, peroneal, foot musclesAtrophy of calf, peroneal, foot, intrinsic hand musclesAtrophy of calf, peroneal, and foot musclesAtrophy of calf, peroneal, and foot musclesAtrophy of calf, peroneal, foot, intrinsic hand musclesNR CMT neuropathy score15NENENE920131412NRNRNRNRNR 9HPT25.7 sNENENE22.7 s31.4 s26.3 sNRNRNRNRNRNRNR Any additional featuresNoNoNoEpilepsy with generalized seizures since adolescenceHand tremorHand tremorHand tremorNoNoNoNoNoNoNR Muscle MRI findingsPredominant signal changes in the anterior and lateral compartments of the lower leg musclesNENENEPredominant signal changes in the anterior and lateral compartments of the lower leg musclesPredominant signal changes in the anterior and lateral compartments of the lower leg musclesPredominant signal changes in the anterior and lateral compartments of the lower leg musclesNENENENENENENE Sural nerve biopsyNENENENEOnion bulbs and degenerating fibers with various myelin abnormalitiesNENEOnion bulbs, reduced density of myelinated axonsNENENENEDemyelinating neuropathy; onion bulb formationNE*M*- male, *F*- female *mo*- months, *y*- years, *D*- decreased, *N*- normal, *L*-left, *R*- right, *9HPT*- nine hole peg test, *NE*- not examined, *NR*- not reported Table 2Electrophysiological recordingsFAMILY AFAMILY BA.II-2A.III-1 (proband)B.II-1B.II-2 (proband)Age at evaluation34 years of age20 years of age30 years of age35 years of age37 years of age46 years of age37 years of ageSensoryCV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)CV (m/s)A (μV)DL (ms)MedianNRNRNRNENENENRNRNRNRNRNRNRNRNR54.95.9NR53.16.2NRUlnarNRNRNRNENENENRNRNRNRNRNRNRNRNR53.12.4NR56.32.4NRSuralNRNRNRNENENENRNRNRNRNRNRNRNRNR43.36NR39.96.4NRMotorCV (m/s)A (mV)DL (ms)FW-L (ms)CV (m/s)A (mV)DL (ms)CV (m/s)A (mV)DL (ms)CV (m/s)A (mV)DL (ms)CV (m/s)A (mV)DL (ms)CV (m/s)A (mV)DL (ms)FW-L (ms)CV (m/s)A (mV)DL (ms)FW-L (ms)Median123.15.13NENENENE8.98.36.484.16.136.54.35.649.316.53.733.839.6143.547.7Ulnar14.72.95.8NE21.912.58.811.16.27.911.72.75.912.52.76.456.310.12.635.445.310.33.343PeronealNRNRNRNENR4.314NRNRNRNRNRNRNRNRNR43.46.54.5NE30.60.74.1NETibialNRNRNRNENENENENRNRNRNRNRNRNRNRNR47.59.54.560.335.944.276*CV* -- nerve conduction velocity, *DL* -- distal latency, *FW-L* -- F-wave measurements, *A* -- amplitude, *NE*- not examined, *NR*- not recorded

The proband's parent (A.II-2) started to walk at the age of 1 year with frequent falls. Foot deformities (high arched feet, thin calves) became apparent in the first decade of life. From the age of 34 years the patient reported weakness in the distal hand muscles with impairment of the fine movements. Neurological examination at the last follow-up (age 34) is presented in Table [1](#Tab1){ref-type="table"}. NCS displayed a demyelinating pattern with secondary axonal degeneration in the lower limbs.

Lower limb musculature of patient A.III-1 was examined using magnetic resonance imaging (MRI) (Fig. [2](#Fig2){ref-type="fig"}b-e). The lateral compartments of the calves, including *peroneus longus* and *brevis* muscles were more severely affected, followed by *extensor digitorum brevis* and *tibialis anterior* muscles. The posterior compartment of the calves seemed relatively preserved. At thigh level the muscles were preserved as well, with slight changes visible in *semimembranosus* and *semitendinosus* muscles.

### Family B {#Sec5}

The proband (B.II-2) is a German individual who was adopted at the age of 1.5 years. The patient first exhibited a slight clumsiness with children's gymnastics at the age of 2--3 years (Table [1](#Tab1){ref-type="table"}). Foot deformities (*pes varus)* were observed at the age of 10 years, leading to walking impairment. After consultation with a child neurologist at youth, B.II-2 first presented in the neurological outpatient clinic at the age of 37 years. At that time, the patient complained of slightly progressive walking impairment and exercise induced muscle cramps in the upper limbs. The neurological examination was consistent with polyneuropathy with a predominant involvement of the lower limbs. The patient underwent surgical correction of foot deformity on the left side at the age of 41. When last examined at the age of 44, the motor and sensory deficits had not progressed significantly. B.II-2 was able to walk 2--3 km with orthopaedic shoes but without further aids. NCS performed at the age of 37 years showed a moderate reduction of motor and sensory amplitudes as well as conduction velocities in the lower limbs and markedly prolonged F-wave latencies, consistent with a primarily demyelinating pathology most pronounced on proximal parts of the motor nerve (Table [2](#Tab2){ref-type="table"}). These remained without any major changes in the examination seven years later, at age 44.

The older sibling (B.II-1, also adopted) was reported to present with foot deformities and slight clumsiness since the age of 2--3 years. Since these complaints have not interfered with everyday activities, the individual was followed up at the age of 46 years. Patient B.II-1 revealed similar, albeit milder clinical features with *pes varus* deformity more pronounced on the right side, an inability to walk on heels, areflexia, but absence of muscle atrophy or sensory deficits (Table [1](#Tab1){ref-type="table"}). As an additional clinical feature, B.II-1 had suffered from recurrent generalized seizures with an onset at the age of 12 years, which reduced markedly upon therapy with valproic acid. NCS revealed only discreet abnormalities with prolonged F-wave latencies in the lower and upper limbs, suggesting a focal demyelinating pathology at the level of the roots or the proximal parts of the motor nerves, but mostly normal motor and sensory amplitudes and conduction velocities. Interestingly, the CVs of the sensory nerves in the upper limbs were normal, while the amplitudes of SNAPs were decreased, suggesting axonal damage. The CVs of the median and ulnar nerves were decreased with normal amplitudes and distal latencies of CMAPs (Table [2](#Tab2){ref-type="table"}).

Both adopted sibs originate from the same biological parents. One of them (B.I-2) was reported to have had a similar disease but no clinical data were available.

Genetic analysis {#Sec6}
----------------

We performed whole exome sequencing (WES) on the proband of the Bulgarian family (A.III-1) (Fig. [1](#Fig1){ref-type="fig"}a) as previous genetic analysis eliminated the *17p*-duplication involving *PMP22* and mutations in 29 common CMT-causing genes. A coverage of 10x over 85% of the sequence was reached using the SeqCap EZ Exome Kit v2 (Roche, Basel, Switzerland) on an Illumina NextSeq500 analyser (Illumina, San Diego, CA). A total of 21,870 sequence variants in protein-coding regions were identified exome-wide. The variant filtering was performed using a dominant disease model and a frequency cut-off of \< 1% in gnomAD and ExAC online genomic databases \[[@CR19]\]. Variants from 329 genes associated with CMT, SMA, HMN, SCA, HSP and ALS were extracted, leading to the identification of a novel variant in *PMP2* p.Met114Thr (c.341C \> T) that co-segregated with the disease phenotype in family A (Fig. [1](#Fig1){ref-type="fig"}a, b). No other candidate variants were identified in the known disease-causing genes.

Following this finding, we performed a genetic screening of *PMP2* in 241 patients with a clinical diagnosis of CMT1 or I-CMT, an unknown genetic cause and mutations in the most common CMT1 genes (*PMP22*, *MPZ* and *GJB1*) previously excluded (Table S1). We identified another novel missense mutation in *PMP2* p.Val115Ala (c.344 T \> C) in a German patient (B.II-2) that co-segregated with the disease in the two affected brothers (Fig. [1](#Fig1){ref-type="fig"}a, b). Their biological parents were not available for segregation analysis. To eliminate the presence of other disease-causing mutations in known CMT-causing genes, whole exome sequencing was performed on the proband (B.II-2) using the same procedure as described above and reaching 96% at 10x coverage. In the resulting 23,844 variants within protein-coding regions we did not identify any other candidates in known CMT-causing genes. Considering the electrophysiological findings in the German patients, we subsequently expanded our mutation screening to a cohort of 352 patients diagnosed with CMT2, but no additional *PMP2* variants were identified.

The newly identified mutations (p.Met114Thr; p.Val115Ala) are not reported in gnomAD. They both target conserved nucleotide (GERP = 5.89; 4.71) and amino acid residues that, interestingly, are adjacent to each other (Fig. [1](#Fig1){ref-type="fig"}c, e). These residues are surrounded by fatty acid coordinating residues (Fig. [1](#Fig1){ref-type="fig"}d, f) \[[@CR15]\]. Both changes were predicted to be disease-causing by the available online mutation prediction algorithms.

The crystal structure of the wildtype PMP2 protein was used to estimate how the mutations could impact protein stability. The "ΔΔG" measurement (Yasara v17.12.24) provides a comparison of the predicted change in free energy between mutated and wildtype proteins \[[@CR20], [@CR21]\]. Positive values indicate an increase in free energy suggesting a destabilization, while negative values point to a stabilizing effect. Both PMP2 p.Met114Thr and p.Val115Ala variants are predicted to have a destabilizing effect on the overall protein structure with a ΔΔG \> 2, which is comparable to the previously reported PMP2 mutations (Fig. [1](#Fig1){ref-type="fig"}e).

Discussion {#Sec7}
==========

Overall, the clinical onset and the rate of progression of the reported PMP2 patients demonstrate broad variability with initial complaints between the first years of life with delayed motor milestones to adolescence \[[@CR11]--[@CR13]\]. Foot deformities and peroneal weakness are invariably present in all affected individuals \[[@CR11]--[@CR13]\]. A comparison between all patients with known *PMP2* mutations is presented in Table [1](#Tab1){ref-type="table"}.

Although the two novel mutations are in close structural proximity, families A and B demonstrate significant variability of disease severity in terms of clinical features and electrophysiologic pattern of involvement. In family A, the onset was very early with distal weakness in lower limbs in the first year of life and delayed walking in patient A.III-1, whereas in family B both affected individuals exhibited only a slight clumsiness and *pes varus* in the first decade of life, that did not interfere much in their subsequent functioning. Regardless of the age at onset the course of the polyneuropathy in both families was quite benign, with preserved ambulation until the last follow-up performed in the 4th--5th decade. Hand muscle weakness appeared in the third-forth decades in the Bulgarian family, while the German patients showed no such signs until their latest follow-up (5th decade). In line with previous reports, the Bulgarian patients exhibited a predominant peroneal involvement in the lower limbs and a more severe weakness of *m. abd. pollicis* in comparison to other hand muscles (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR14]\].

Nerve conduction studies of the PMP2 patients reported up to now demonstrate classical features of demyelinating polyneuropathy with very slow CVs of the motor and sensory nerves below 20 m/s and secondary axonal degeneration \[[@CR12]--[@CR14]\]. NCS in all examined affected individuals presented in this report were consistent with a demyelination of variable severity and location. Electrophysiological recordings in the Bulgarian family revealed very slow CVs of the motor fibres of median and ulnar nerves, not exceeding 15 m/s (Table [2](#Tab2){ref-type="table"}), while CVs of the motor nerves in the lower limbs and CVs of the sensory nerves of both upper and lower limbs were unobtainable, as previously reported \[[@CR12], [@CR13]\]. In contrast, NCS performed in the fifth decade in the German patients displayed very mild changes, consistent with a primarily demyelinating focal pathology most pronounced at the proximal parts of the motor nerves and sensory axonal degeneration in the upper limbs in one of the patients, which is in line with their milder clinical features. Because of this unusual NCS pattern, patients in family B do not fulfill the classical criteria neither for demyelinating neuropathy (except for the prolonged F-wave latencies), nor for axonal neuropathy. Although the reason for this peculiar NCS features remain unknown, our findings suggest that *PMP2* testing should come into consideration in patients with even subtle electrophysiological signs of demyelination.

The muscle MRI in patient A.III-1 showed a more severe fatty replacement in the calf muscle compared to the thigh muscle, which is consistent with a length-dependent degeneration of the axons. As observed previously, the peroneal muscles were more severely affected compared to tibialis anterior muscles \[[@CR12]\]. The posterior lower leg compartment was less involved, which is similar to what is observed in CMT1A patients.

The three previously reported PMP2 mutations (p.Ile43Asn, p.Thr51Pro, p.Ile52Thr) cluster in two neighbouring beta-strands β2-β3 (Fig. [1](#Fig1){ref-type="fig"}e). Crystallography studies show that all of them induce an increased aggregation tendency and a significant destabilization of the tertiary structure of the protein, with p.Thr51Pro showing the strongest effect \[[@CR16]\]. The two new mutations (p.Met114Thr and p.Val115Ala) form a second mutational cluster on β9 (Fig. [1](#Fig1){ref-type="fig"}e). Like the known mutations, they affect conserved residues amongst the PMP2 orthologs and throughout the FABP family (Fig. [1](#Fig1){ref-type="fig"}c, d). The introduction of residues with different polarity (p.Met114Thr) or flexibility (p.Val115Ala) could disturb the protein structure in a similar manner as demonstrated with previously reported mutations, however further studies are required to confirm this hypothesis \[[@CR16], [@CR22]\]. PMP2 expression is restricted to Schwann cells, as reported in mice and confirmed by our immunoblotting experiments (data not shown) \[[@CR18]\]. Unfortunately, we did not detect ectopic PMP2 expression in EBV-transformed lymphocytes from patients and controls. Therefore, we could not investigate the validity of the in silico predictions and whether the two missense mutations cause protein destabilisation or possible aggregation in vivo*.*

Concerning its fatty acid binding properties, PMP2 was shown to have affinity towards key components of the myelin sheath including palmitate, oleate and cholesterol \[[@CR16], [@CR23]\]. Importantly, the three known CMT1-causing mutations alter the conformational dynamics, leading to differential fatty acid binding properties when compared to wildtype PMP2 \[[@CR16]\]. The new mutations lie in a protein region structurally surrounded by fatty acid-coordinating residues (p.Arg107, p.Arg127, p.Tyr129) (Fig. [1](#Fig1){ref-type="fig"}f), suggesting their potential detrimental effect on ligand binding.

The mechanism through which *PMP2* mutations cause CMT is currently unknown. This is partly due to the lack of complete understanding of the function of PMP2. A Pmp2 knock-out (*Pmp2*^*KO*^) mouse model showed that the protein is not required for the formation of the myelin sheath \[[@CR18]\]. The *Pmp2*^*KO*^ mice largely resemble their wildtype littermates, unlike what is observed in corresponding studies with *Mpz* or *Pmp22* null-mice \[[@CR18], [@CR24], [@CR25]\]. However, the myelin was found to be thinner than in wildtype mice and did not recover as well under nerve crush injury, suggesting possible functions for Pmp2 in the myelin repair \[[@CR18]\]. Together with the findings from crystallography studies these data suggest that the complete loss of function is not the disease driving mechanism, likely the mutations induce a gain of toxic function resulting in an unstable myelin sheath \[[@CR16]\].

Conclusion {#Sec8}
==========

Here we report two mutations in *PMP2* as novel causes of dominant CMT that is primarily demyelinating in nature. The new mutations affect adjacent amino acid residues, revealing a novel mutation cluster in PMP2. Importantly, we expand the clinical and electrophysiological spectrum of *PMP2*-related neuropathy with the identification of very mildly affected individuals who have only subtle proximal demyelination and focal pattern of distribution along peripheral nerves. Our findings contribute to an improved clinical and genetic diagnosis of patients and families with inherited peripheral neuropathies.

Methods {#Sec9}
=======

Clinical and electrophysiological evaluation {#Sec10}
--------------------------------------------

The patients were interviewed to obtain information on family history, age at onset, initial symptoms, distribution of muscle weakness, disease progression, and current disability. The four mutation carriers were subjected to neurological examination including testing of muscle strength according to the Medical Research Council (MRC) grading method. Serial clinical and electrophysiological evaluation spanning 17 years was performed on one of the patients (A.III-1).

Magnetic resonance imaging {#Sec11}
--------------------------

Lower limb musculature of patient A.III-1 was examined using a 3 T MRI scanner (Siemens Magnetom Verio 3.0 T, Tarrytown, USA). Non-enhanced T1, T2 and proton density fat saturated sequences were applied in pelvis, bilateral thighs and lower legs.

Patient cohorts {#Sec12}
---------------

The initial cohort consisted of isolated patients with a clinical diagnosis of demyelinating (*n* = 174) or intermediate (*n* = 67) peripheral neuropathy. Based on the clinical findings in family B we expanded the *PMP2* screening to 352 additional CMT2 index patients. The most common causes of CMT, including *17p* duplication and mutations in *PMP22, MPZ, MFN2* and *GJB1* were excluded prior to the onset of this study*.* The full list of genes excluded prior to whole exome sequencing (WES) analysis in patients A.III-1 and B.II-2 is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Whole exome sequencing {#Sec13}
----------------------

WES of individuals A.III-1 and B.II-2 were performed at the Neuromics Support Facility of the VIB Centre for Molecular Neurology, Antwerp, Belgium. The sequencing was done using SeqCap EZ Exome Kit v3 (Roche, Basel, Switzerland) on an Illumina NextSeq500 system (Illumina, San Diego, CA, USA) to an average of 10-fold coverage over 85% and 96% of the targeted regions for A.III-1 and B.II-2 respectively. The paired-end reads were then aligned to the human reference genome GRCh37/hg19 using Burrows-Wheeler aligner (0.7.15-r1140) \[[@CR26]\]. In both patients the variant calling was performed using the genome analysis toolkit (GATK) versions 3.7 (A.III-1) and 4.0.6.0 (B.II-2) \[[@CR27]\]. Additional individual analyses were done using the sequence alignment/map tools (SAMtools, v1.6) for A.III-1 and Strelka (v2.9.9) for B.II-2 \[[@CR28], [@CR29]\]. GenomeComb software was used to extract the sequencing gaps in known CMT1-causing genes and to perform variant annotation and filtering \[[@CR30]\]. In both individuals sequence gaps were closed in the CMT1 causing genes using Sanger sequencing.

*PMP2* sequencing {#Sec14}
-----------------

All four exons of *PMP2* (RefSeq NM_002677.4) were amplified using the primers provided in Additional file [1](#MOESM1){ref-type="media"}: Table S2. The PCR products were subsequently purified with ExoSAP-IT (Affymetrix, Santa Clara, CA). We performed Sanger sequencing using the BigDye v3.1 Terminator cycle sequencing kit (Thermo Fischer Scientific, Waltham, MA). The fragments were electrophoretically separated on a 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA) with the alignment and analysis performed using SeqMan v5.07 (DNAStar, Madison, WI, USA). The nucleotide and amino acid numbering used in this study are according to the *PMP2* mRNA (NM_002677.4) and protein (CAG46538.1) sequences available at the National Centre for Biotechnology Information, and mutation description was according to Human Genome Variation Society nomenclature (<http://varnomen.hgvs.org/>).

Prediction of mutation pathogenicity {#Sec15}
------------------------------------

To predict the possible impact of the mutation we used a combination of PolyPhen2 (v2.2.2), MutationTaster (v2013), SIFT (v6.2.0) and CADD (v1.3) \[[@CR31]--[@CR34]\]. The scores given by these programs are provided in Additional file [1](#MOESM1){ref-type="media"}: Table S3.

Mutation modelling {#Sec16}
------------------

The modelling of wild-type and mutant proteins was performed using Yasara v17.12.24 and Chimera v1.12 on the PMP2 (PDB ID: 3NR3) crystal structure \[[@CR20], [@CR35]\]. The effect of the amino acid change to the protein structure was estimated with FoldX v3.0b4 using standard parameters \[[@CR21]\].

Additional file
===============

 {#Sec17}

Additional file 1:**Table S1.** Genomic defects and genes analyzed prior to WES. **Table S2.** Primers used for PMP2 screening. **Table S3.** Scores from the pathogenicity prediction programs. (PDF 62 kb)

ALS

:   Amyotrophic lateral sclerosis

CMAP

:   Compound muscle action potential

CMT

:   Charcot-Marie-Tooth

EBV

:   Ebstein-Barr virus

EMG

:   Electromyography

ExAC

:   Exome Aggregation Consortium

GJB1

:   Gap junction beta-1

gnomAD

:   Genome Aggregation Database

HMN

:   Hereditary motor neuropathy

HSP

:   Hereditary spastic paraplegia

MBP

:   Myelin basic protein

MFN2

:   Mitofusin 2

MPZ

:   Myelin protein zero

MRC

:   Medical Research Council

MRI

:   Magnetic resonance imaging

NCS

:   Nerve conduction studies

NCV

:   Nerve conduction velocities

NGS

:   Next generation sequencing

PDB

:   Protein data bank

PMP2

:   Peripheral myelin protein 2

PMP22

:   Peripheral myelin protein 22

SCA

:   Spinocerebellar ataxia

SMA

:   Spinal muscular atrophy

WES

:   Whole exome sequencing

GERP

:   Genomic evolutionary rate profiling

SIFT

:   Sorting tolerant from intolerant

CADD

:   Combined annotation dependent depletion
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